Literature DB >> 21868395

Pharmacokinetics of sulfobutylether-β-cyclodextrin (SBECD) in subjects on hemodialysis.

David R Luke1, Nolan D Wood, Konrad E Tomaszewski, Bharat Damle.   

Abstract

BACKGROUND: The disposition of sulfobutylether-β-cyclodextrin (SBECD), the solubilizing excipient in intravenous (i.v.) voriconazole, was assessed in seven male subjects with end-stage renal disease on hemodialysis and six subjects with normal renal function.
METHODS: All subjects received twice-daily i.v. voriconazole at the standard voriconazole dose [6 mg/kg (96 mg/kg SBECD) every 12 h (Q12h) on Day 1 followed by 3 mg/kg (48 mg/kg SBECD) Q12h on Days 2-4, with a single i.v. dose on the morning of Day 5]. Subjects were sampled at selected pre-dose trough times, at selected times after infusions and intensively on Day 3 (non-dialysis) and Day 4 (dialysis with high-flux membranes). Compartmental analyses were performed by NONMEM.
RESULTS: SBECD disposition was characterized by a two-compartment model. In renal failure, mean central (V(1)) and peripheral compartment volumes (V(2)) were 9.9 and 6.5 L, respectively. In normal subjects, V(1) and V(2) were 9.6 and 5.2 L, respectively; SBECD clearance (CL) was 130 mL/min. CL in renal failure off-dialysis was 2.6 and 48 mL/min during dialysis; mean half-life decreased from 79 to 5 h during dialysis (normal subjects: 2.1 h).
CONCLUSION: Hemodialysis can significantly reduce levels of SBECD in subjects with end-stage renal disease.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21868395     DOI: 10.1093/ndt/gfr472

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  11 in total

Review 1.  Remdesivir in Patients with Acute or Chronic Kidney Disease and COVID-19.

Authors:  Meagan L Adamsick; Ronak G Gandhi; Monique R Bidell; Ramy H Elshaboury; Roby P Bhattacharyya; Arthur Y Kim; Sagar Nigwekar; Eugene P Rhee; Meghan E Sise
Journal:  J Am Soc Nephrol       Date:  2020-06-08       Impact factor: 10.121

2.  Antinociceptive effects of bupivacaine and its sulfobutylether-β-cyclodextrin inclusion complex in orofacial pain.

Authors:  Juliana Souza de Freitas Domingues; Silmara Martins Dias Dos Santos; Julia das Neves Rodrigues Ferreira; Bianca Miguel Monti; Darciane Favero Baggio; Wagner Hummig; Erika Ivanna Araya; Eneida de Paula; Juliana Geremias Chichorro; Luiz Eduardo Nunes Ferreira
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2022-08-01       Impact factor: 3.195

3.  Safety and Tolerability of Remdesivir in Patients with End-stage Renal Disease on Maintenance Hemodialysis.

Authors:  Maulin K Shah; Mital Parikh; Dhavalkumar Prajapati; Vivek B Kute; Punam Bhende; Abhishek Prajapati; Sunil H Chhajwani; Krushan Yajnik; Jaishree Ganjiwale; Jyoti G Mannari; Bhalendu Vaishnav
Journal:  Indian J Crit Care Med       Date:  2022-05

4.  Evaluation of sulfobutylether-β-cyclodextrin (SBECD) accumulation and voriconazole pharmacokinetics in critically ill patients undergoing continuous renal replacement therapy.

Authors:  Tyree H Kiser; Douglas N Fish; Christina L Aquilante; Joseph E Rower; Michael F Wempe; Robert MacLaren; Isaac Teitelbaum
Journal:  Crit Care       Date:  2015-02-03       Impact factor: 9.097

5.  Safety of Remdesivir in Patients With Acute Kidney Injury or CKD.

Authors:  Sayali Thakare; Chintan Gandhi; Tulsi Modi; Sreyashi Bose; Satarupa Deb; Nikhil Saxena; Abhinav Katyal; Ankita Patil; Sunil Patil; Atim Pajai; Divya Bajpai; Tukaram Jamale
Journal:  Kidney Int Rep       Date:  2020-10-10

6.  Use of Remdesivir in Patients With COVID-19 on Hemodialysis: A Study of Safety and Tolerance.

Authors:  Dhanapalan Aiswarya; Venkatesh Arumugam; Thanigachalam Dineshkumar; Natarajan Gopalakrishnan; Tanuj Moses Lamech; Govindasamy Nithya; Bhagavatula V R H Sastry; Paulpandian Vathsalyan; Jeyachandran Dhanapriya; Ramanathan Sakthirajan
Journal:  Kidney Int Rep       Date:  2020-12-18

7.  Therapeutic dilemmas in dialysis patients hospitalized for COVID-19: balancing between nihilism, off-label treatment and side effects.

Authors:  Mariusz Kusztal; Marek Myślak
Journal:  Clin Kidney J       Date:  2021-01-11

8.  Osmotic tubulopathy in a patient with COVID-19 treated with remdesivir.

Authors:  Janewit Wongboonsin; Sujal I Shah; Francisco M Marty; David B Mount; Helmut G Rennke; Naoka Murakami
Journal:  Kidney Int Rep       Date:  2021-05-12

9.  Remdesivir administration for Japanese COVID-19 patients undergoing maintenance hemodialysis: a retrospective observation with six case reports.

Authors:  Jun Ito; Moritsugu Kimura; Tomoyuki Toya; Konomi Isozumi; Atsuro Kawaji; Yudai Isozaki; Masafumi Fukagawa
Journal:  Ren Replace Ther       Date:  2022-04-11

10.  Evaluation of intravenous voriconazole in patients with compromised renal function.

Authors:  Craig M Lilly; Verna L Welch; Thomas Mayer; Paul Ranauro; Joanne Meisner; David R Luke
Journal:  BMC Infect Dis       Date:  2013-01-16       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.